Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

229.39
+0.75610.33%
Post-market: 230.310.9178+0.40%19:30 EDT
Volume:3K
Turnover:654.13K
Market Cap:464.86M
PE:- -
High:230.31
Open:229.91
Low:229.39
Close:228.64
52wk High:244.35
52wk Low:160.91
Shares:2.03M
Float Shares:2.03M
Volume Ratio:0.25
T/O Rate:0.14%
Dividend:0.96
Dividend Rate:0.42%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sanofi, Regeneron Could Extend Dupixent Patent

Dow Jones
·
Sep 09

Regeneron Pharmaceuticals, Inc. : Bmo Raises Target Price to $920 from $800

THOMSON REUTERS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Waters (WAT) and Amgen (AMGN)

TIPRANKS
·
Sep 09

Sino Biopharmaceutical Stock Slides 4.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 09

LIVE Markets-Europe Before the Bell: Eyeing Another Soft Open

Reuters
·
Sep 09

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

Money Quote: a Bad Day for Amgen Stock

Dow Jones
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 09

LIVE Markets-Back to the Post-Summer Grind: Stocks End Red

Reuters
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09